Drug intelligence / Profile preview

L-cystine-bis-glycine

Development stage: Unknown
Lead developer: ProImmune
Modality: Peptides
Administration: Oral

Overview

FT061452 (ProImmune) is a novel glutathione precursor consisting of L-cystine-bis-glycine. It is designed to increase intracellular glutathione (GSH) levels more effectively than N-acetylcysteine (NAC) by providing the rate-limiting amino acid cysteine in a stable, dipeptide-linked form (cystine) along with glycine. Glutathione is a critical antioxidant that protects cells from oxidative stress, and its levels typically decline with age, contributing to various chronic conditions. FT061452 is primarily investigated as a dietary supplement to improve antioxidant status and support immune function.

Brand names: ProImmune
Other names: N,N'-bis-glycyl-L-cystineGCGglycyl-cystine-glycine

Targets

GSH (Glutathione)

Beyond the preview

Go deeper on L-cystine-bis-glycine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-cystine-bis-glycine.

Explore the full profile